Houston and former space rival are advancing biotech startups

Guest Column

Formerly competitors and collaborators in the space race, Houston and Huntsville, Alabama, are now moving the needle on biotech. Getty Images

Before scientists flocked to Boston and Silicon Valley; a tech boom occured in the American south that served as a defining moment for the United States: the Space Race.

At the time, two cities were the epicenters of mankind's desire to elevate its existence into the stars. Astronauts controlled the path of rockets that were built in Huntsville, Alabama, while radioing back and forth with Mission Control in Houston, Texas.

Today, the two cities are still aligned, but the final frontier is closer to home. Houston and Huntsville are currently flourishing in the scope of biotechnology, using the innovative research of thousands of scientists, academics, and clinicians to further human knowledge

Houston is the home to the world's largest medical center — the Texas Medical Center, or TMC — and an impressive community developing cutting-edge companies ranging from med to biotech. However, Huntsville is hot on its heels.

Turning an infrastructure initially dedicated to aerospace and aeronautical innovation into an emerging bioscience hub, Huntsville boasts around 50 biotech companies and a genomic research institute. The ecosystem has the highest concentration of STEM workers per capita in the country and is rallied around a collaborative research environment that boasts an impressive tech portfolio, including resident companies like Blue Origin, Facebook, and Google, while still managing to embody southern hospitality.

Mirroring the concerted efforts of the past, my Houston-born startup, Van Heron Labs, has recently taken a leap of faith in moving much of their laboratory operations to Huntsville, while many core team members remain in Houston. Being frustrated with the options for available and affordable lab space in Houston, the completely bootstrapped Van Heron Labs decided to stretch one foot into Alabama while the other stays rooted in the TMC ecosystem.

One positive upside to the shift to remote work in light of the COVID-19 pandemic are new opportunities for company employees, investors, and mentors to be physically separated, while collaborating and retaining productivity. These new dynamics of distance have allowed Van Heron Labs to expand their technical operations while maintaining ties to Houston.

VHL has recently moved into the HudsonAlpha Institute for Biotechnology, where they continue to develop their technology surrounding improved culture media, which hasn't changed much since scientists saw the publication of the first Peanuts comic. Recently, VHL has established a collaborative partnership with fellow Huntsville biotech Foresight Biosciences, and the two will be exploring a wealth of industries together.

Despite the distance, VHL still continues heavy involvement in the Houston ecosystem. My co-founder, Alec Santiago, is the current Director of non-profit, Enventure, and uses his experiences of establishing a biotech startup to help prepare the students around him to do the same.

Additionally, VHL currently has 17 interns, including current and former University of Houston students, Rice University graduate students, and even a local physics PhD. VHL has also long been in talks with companies in TMC, where they have established connections dedicated to growth. Ultimately, they hope to bridge the two cities and help give each access to new ideas, resources, funding, and mentorship.

Too often, emerging biotech startups struggle to get off the ground, and a lack of capital limits what could grow to be great ideas. To foster the growth of innovators around the nation several cities are primed to step in and welcome researchers. Institutions within Alabama's biotech ecosystem are leading the movement.

For just $188 a month, biotech startup companies located at HudsonAlpha campus can enjoy their own office space, and access to tailored programming which includes commercial IP assessments, regular investor forums and pitch opportunities, membership in supporting bioscience organizations, discounted laboratory supplies, as well as help with public relations, human relations, finding mentors, capital, and legal help.

VHL has taken full advantage of these opportunities, while maintaining a presence in Houston, and urges others to do the same. The lifting of our nation's innovators as a whole is a positive movement, and one that can increase access to many bright minds. Just as in the space race, working together regardless of geography can offer unlimited potential and may even take us to an entirely new plane.

------

Rebecca Vaught is the co-founder of Van Heron Labs.

This week's Houston innovators to know includes Rebecca Vaught of Van Heron Labs, Samantha Lewis of GOOSE Capital, and Camilo Mejia of Enovate Upstream. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: Houston entrepreneurs are like the city itself — resilient. And much like the wildcatters that preceded them, they are self-starters and hard working. This week's roundup of Houston innovators all reflect these attributes — whether they're founding their company amid a global pandemic or rebranding a 15-year-old investing institution.

Rebecca Vaught, co-founder of Van Heron Labs

Entrepreneur hopes to bring microbiology into the future with her Houston-based, pandemic-founded startup

Rebecca Vaught started her biotech company just ahead of COVID-19, but she shares on the Houston Innovators Podcast that it's meant more opportunities than challenges. Photo courtesy of Van Heron Labs

When Rebecca Vaught's accelerator program shutdown due to COVID-19, she didn't let that stop the progress for here fledgling biotech business. In fact, it was a turning point.

"A lot of people probably would have seen that as the stopping point but that was actually the beginning of the company," Vaught says on the Houston Innovators Podcast. "What it allowed us to do was actually establish the lab and do the hard work."

As Vaught says, the biotech company, Van Heron Labs, is what it is thanks to the pandemic — not just in spite of it. Click here to read more and listen to the podcast episode.

Samantha Lewis, director of GOOSE Capital

Samantha Lewis, director of GOOSE Capital, shares how the investment firm has rebranded and is focused on the future. Photo courtesy of GOOSE

A prominent investment group, GOOSE Capital — previously known as GOOSE Society of Texas — has opted for a rebranding to move itself into the future for Seed and Series A investment. Samantha Lewis, director of GOOSE, explains the decision means more than just a new name and upgraded website.

"As for the future of GOOSE Capital, expect great things," she tells InnovationMap. "Our rebranding is one of the many steps we are taking to solidify our position in the Seed and Series A venture scene."

Rather than operating as a fund, the GOOSE Capital model enables its corps of investors comprised of Fortune 500 execs and successful serial entrepreneurs direct access to a portfolio of startups and investment deals. At the same time, GOOSE's portfolio companies are able to receive support from these investors. Click here to read more.

Camilo Mejia, CEO and founder of Enovate Upstream

Houston entrepreneur plans to revolutionize and digitize the energy industry

Camilo Mejia, CEO and founder of Houston-based Enovate Upstream, has big plans for increasing efficiency across the oil and gas sector. Photo courtesy of Enovate

Enovate Upstream announced its new artificial intelligence platform that aims to digitize the oil and gas sector to provide the best efficiency and return on investment at every stage of the supply chain cycle — from drilling and production to completion.

"We see a better future in the oil and gas industry," Mejia shares in an interview with InnovationMap. "Our team worked in various roles in O&G, and we don't think the industry will end up as some people may think. The future will be different and digitized, we are just here to facilitate that transition to give back to the industry that gave us a lot."

The company's proprietary cloud-based ADA AI digital ecosystem is challenging the assumptions of the industry by using new technology powered artificial intelligence to provide historical data with AI to give real-time production forecasting. Thanks to the cloud, users can access the information anywhere in the world. Click here to read more.

Rebecca Vaught started her biotech company just ahead of COVID-19, but she shares on the Houston Innovators Podcast that it's meant more opportunities than challenges. Photo courtesy of Van Heron Labs

Entrepreneur hopes to bring microbiology into the future with her Houston-based, pandemic-founded startup

HOUSTON INNOVATORS PODCAST EPISODE 40

While startups everywhere are struggling to adapt in the tumultuous times of COVID-19, Rebecca Vaught and her company, having launched just ahead of the pandemic, don't actually know any other way of existing.

After watching some of her friends thrive in Houston's life science ecosystem, she knew Houston was the place she wanted to start the company that she'd been envisioning and plotting for years. She took a chance on the city, moved in, and began Enventure's Biodesign accelerator. The program shutdown as COVID-19 spread, much like other programs, but Vaught wasn't going to let that stop her momentum.

"A lot of people probably would have seen that as the stopping point but that was actually the beginning of the company," Vaught says on the Houston Innovators Podcast. "What it allowed us to do was actually establish the lab and do the hard work."

As Vaught says, the biotech company, Van Heron Labs, is what it is thanks to the pandemic — not just in spite of it.

"While it's been challenging, the pandemic — in a lot of ways — is the only thing we've ever known and it's a lot of reason why the company has taken off and been successful," Vaught says on the show.

She runs the company with co-founder Alec Santiago and a team of 17 interns — all located across the country. Vaught herself is currently residing in Huntsville, Alabama, after struggling to find lab space in Houston. However, the relocation has been a blessing in disguise.

"Both ecosystems are extremely unique and both bring something different to the table," she says. "My next mission, through my lived experience, is igniting or uniting the Houston and Huntsville biotech ecosystems."

On the episode, Vaught explains how the two cities — each representing key parts of space exploration history and burgeoning tech scene — complement each other. She also shares her plans for growth and the need to bring microbiology into the future.

Listen to the full interview below — or wherever you get your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

5 must-read innovation headlines: Pharma giant considers Houston hub + more

Trending news

Editor's note: With May coming to a close, it's time to look back at the biggest innovation headlines for the second half of the month. Major moves were made in May, with NuScale Power entering the market, Persona AI inking a deal with Under Armour, and a pharma giant considering Houston for its next manufacturing hub. Here are the most-read InnovationMap stories published May 15-29, 2026:

1. Pharma giant considers Houston for $1 billion manufacturing campus

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub. According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

2. Modular nuclear reactor co. NuScale Power moves into Houston market

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

3. Persona AI teams with Under Armour to protect next-gen robots

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions. Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

4. Houston quantum energy chip startup emerges from stealth with $12M round

Houston-based Casimir has emerged from stealth with a $12 million seed round to commercialize its quantum energy chip. The round was led by Austin-based Scout Ventures. Lavrock Ventures, Cottonwood Technology, Capital Factory, American Deep Tech, and Tim Draper of Draper Associates also participated in the round. The oversubscribed round exceeded the company’s original $8 million target.

5. Global summit spotlights Houston's growing role in brain health, innovation

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. The summit, held June 9-10 at the Texas Medical Center's Helix Park, will bring together more than 500 executives, researchers, policymakers and innovators from around the world to discuss the global brain economy.

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

View All Listings